Pritelivir, an investigational antiviral for herpes simplex virus, demonstrated strong efficacy in a phase 3 trial, with 62.7% of immunocompromised patients achieving lesion healing. The ...

Cold sore-causing HSV-1 doesn't just hijack cells it reconfigures the entire architecture of our DNA to aid its invasion. Researchers discovered that it actively reshapes the 3D structure of the human ...